Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~* Subject had a clinical diagnosis of psoriasis for at least 6 months, had moderate to severe plaque psoriasis.~* Subject was able and willing to self-administer sc injections or had available qualified person(s) to administer sc injections~Exclusion Criteria:~* Subject had previously received anti-TNF therapy.~* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy~* Subject cannot avoid excessive sun exposure~* Subject is taking or requires oral or injectable corticosteroids~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Female subject who is pregnant or breast-feeding or considering becoming pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).